Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab

Table 3 Multivariate logistic regression analysis

Factor	Odds ratio	95% confidence interval	p value
ECOG PS score ≥ 2	1.44	0.57–3.59	0.4366
Stage: IV, recurrence	1.65	0.61–5.02	0.3357
PD-L1 50–89%	1.91	0.88–4.30	0.1011
Steroid use	5.86	1.32–31.8	0.0200
Metastasis pleural effusion	2.68	1.15–6.35	0.0228
C-reaction protein (< 1.0 mg/dl)	2.17	1.03–4.68	0.0402

ECOG PS Eastern Cooperative Oncology Group performance status, PD-L1 programmed cell death ligand 1

ISSN: 1471-2407